Aura Biosciences (AURA) Cash from Operations (2020 - 2026)

Aura Biosciences has reported Cash from Operations for 7 years, with the latest figure at 29893000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 27.99% year-over-year to 29893000.0; the trailing twelve-month figure through Mar 2026 stood at 91280000.0 (down 15.97% YoY), and the FY2025 full-year result was 84742000.0, down 6.19% from the prior year.
• Cash from Operations for Q1 2026 stood at 29893000.0, down from 20469000.0 in the prior quarter.
• The five-year high for Cash from Operations was 10628000.0 in Q2 2022, with the low at 29893000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 18405176.47 across 5 years, with a median of 17387000.0 in 2023.
• Annual changes were most pronounced in 2022 — Cash from Operations tumbled 195.89% — and 2025, when it climbed 14.54%.
• Aura Biosciences' Cash from Operations stood at 18013000.0 in 2022, then increased by 3.48% to 17387000.0 in 2023, then slumped by 37.76% to 23952000.0 in 2024, then gained by 14.54% to 20469000.0 in 2025, then sank by 46.04% to 29893000.0 in 2026.
• The last three Cash from Operations figures came in at 29893000.0 (Q1 2026), 20469000.0 (Q4 2025), and 20144000.0 (Q3 2025), per Business Quant data.